Apotex wins the first US FDA tentative approval for generic semaglutide

Apotex announced on April 10, 2026 that it received the first US Food and Drug Administration tentative approval for an abbreviated new drug application (ANDA) covering semaglutide injection, a generic version of Novo Nordisk's Ozempic ^[1][2]. The product was developed with Orbicular Pharmaceutical Technologies, a company headquartered in India ^[1][2].

Tentative approval is not the same as approval to sell. The FDA uses the term when a generic meets all statutory and regulatory requirements for approval but cannot be marketed in the United States because patents or exclusivities tied to the brand-name reference drug are still in force ^[1]. In practical terms, Apotex now has a product the FDA has reviewed and found acceptable, and it is positioned to be among the first to launch once Novo Nordisk's US protections lapse ^[1].

The sources do not say when that will happen. No US patent expiration date, launch date, price, or list of pen strengths appears in the available reporting, so those details are not yet known.

What the approval involved

Semaglutide is a peptide, which is harder to copy than a simple small-molecule pill. "Achieving technical equivalence for complex peptide products requires deep scientific rigor, advanced analytical precision, and a highly disciplined development approach," said M. S. Mohan, PhD, managing director of Orbicular Pharmaceutical Technologies, in the companies' news release ^[2]. The development work involved advanced analytical characterization and process control intended to show the copy matches the brand product ^[2].

Outside the US, generic competition has already started. Numerous generic semaglutide products launched in India in March 2026, including from Dr Reddy's, Zydus, Alkem, Sun Pharma and Glenmark, after Novo Nordisk's core Indian patent expired ^[1]. That does not affect what US pharmacies can dispense.

Meanwhile, Novo Nordisk is moving in the other direction on the brand side. The FDA approved a higher 7.2 mg dose of Wegovy (semaglutide), called Wegovy HD, on March 20, 2026 for weight loss and long-term weight maintenance in certain adults, under the Commissioner's National Priority Voucher pilot program, and the product launched in the US in April 2026 ^[1].

Why it matters for patients

The practical effect for people filling prescriptions today is zero. Nothing about this tentative approval changes what is on pharmacy shelves, what insurance covers, or what a month of Ozempic costs right now ^[1].

The longer-term signal is about price and access. When generics arrive in this drug class, payer behavior can shift quickly: after generic liraglutide became available, coverage for the brand-name version dropped by nearly 90%, according to reporting cited by Drug Topics ^[2]. The first generic liraglutide for weight loss was approved in August 2025, and a generic version for type 2 diabetes launched earlier that year ^[2].

Cost pressure in this category is real. GLP-1 spending has grown by more than 500% since 2018, and researchers project the market could nearly double over the next decade as these drugs expand into uses such as chronic kidney disease and cardiovascular health ^[2]. At the same time, prior authorization requirements for GLP-1 medications reached nearly 100% across many plans by 2025, and out-of-pocket costs have risen as Inflation Reduction Act changes to Medicare Part D pushed plans toward tighter coverage and higher cost-sharing on expensive brand drugs ^[2].

There is also a safety angle. The FDA has stepped up enforcement against compounded semaglutide marketing, issuing warning letters to 30 telehealth companies for misleading claims, including implying compounded versions are identical to FDA-approved products ^[2]. The agency has said compounded drugs do not go through the same premarket review for safety and quality that generics do, and litigation from brand manufacturers has surfaced compounded samples with impurities as high as 86% ^[2]. An FDA-reviewed generic, when it eventually launches, would be a reviewed alternative rather than an unapproved one.

What happens next

• March 2026: Generic semaglutide launched in India after the core Indian patent expired ^[1].
• March 20, 2026: FDA approved Wegovy HD (semaglutide 7.2 mg); US launch followed in April 2026 ^[1].
• April 10, 2026: Apotex received first US tentative approval for generic semaglutide injection ^[1][2].
• Date unknown: Final approval and US launch depend on expiration of Novo Nordisk's patents and exclusivities; no timeline is given in the sources ^[1][2].